Evaluation levels of sphingosine, sphingosine-1-phosphate, and interleukin 2 and 3 in leukemia patients..

Abstract

Author(s): Hala F. Hassan, Safaa A. Faraj, Muthana I. Maleek, Zainulabdeen AL-Badri

Sphingosine is the major naturally occurring base present in sphingolipids. It forms a primary part of sphingolipids, a class of cell membrane lipids that include sphingomyelin, an important phospholipid. Sphingosine-1-Phosphate (S1P) is a signaling sphingolipids, also known as glycosphingolipid. It is also referred to as a bioactive lipid mediator. The expression and localization of S1P receptors is dynamically regulated and controls immune cell trafficking. In vertebrates, S1P is found in the extracellular milieu and interacts with cell-surface receptors to regulate an array of cellular responses, including cell migration, differentiation and survival. Targeting various signaling pathways is a potential neoteric therapeutic for the treatment of leukemia. "Sphingosine and sphingosine 1 phosphate" are expressed in large amounts by leukemia cells. Leukemia is a group of blood malignancies that frequently start in the bone marrow and produce a lot of aberrant blood cells. Blasts, or leukemia cells, are the term for these immature blood cells. The study was participating 80 people (40 leukemia patients and 40 as healthy control group).

Result showed highly significant mean values at p ≤ 0.05 of SPH (7.6), IL2 (283.2), and IL3 (196.1) in patients when compared with controls (3.9, 95.2, 145.5) respectively and S1P increased in patients but not significant. The association values of SPH, SIP, IL2 and IL3 in types of leukemia showed highly significant only in IL2 only. Therefore, can concluded the SPH increased with leukemia and led to development of leukemia because it is associated as signaling for cell proliferation with increasing levels of IL2-3.

Share this article